Prophylaxis of Genital Herpes
For patients with recurrent genital herpes, daily suppressive antiviral therapy with valacyclovir 500 mg once daily, famciclovir 250 mg twice daily, or acyclovir 400 mg twice daily is recommended to prevent recurrences and reduce transmission to sexual partners.
Indications for Suppressive Therapy
Suppressive therapy should be discussed with every patient with HSV-2 infection 1. This approach is particularly indicated for:
- Patients with frequent recurrences (≥6 episodes per year) 1, 2
- Patients in serodiscordant relationships where transmission prevention is a priority 3
- Patients with severe recurrences affecting quality of life 4
Key efficacy data: Daily suppressive therapy reduces recurrence frequency by ≥75% 1, 2. In the landmark transmission study, once-daily valacyclovir 500 mg reduced symptomatic HSV-2 transmission by 75% (hazard ratio 0.25) and overall HSV-2 acquisition by 48% in heterosexual discordant couples 3.
Recommended Suppressive Regimens
First-Line Options (Immunocompetent Patients):
- Valacyclovir 500 mg once daily 1
- Valacyclovir 1000 mg once daily 1
- Famciclovir 250 mg twice daily 1
- Acyclovir 400 mg twice daily 1, 2
Important caveat: Valacyclovir 500 mg once daily appears less effective in patients with very frequent recurrences (≥10 episodes per year); use higher doses or twice-daily regimens in this population 1.
HIV-Infected Patients:
Valacyclovir 500 mg twice daily is specifically recommended (not once daily) 4. Alternatively, use twice-daily regimens of acyclovir or famciclovir 4.
Duration and Monitoring
- Safety established: Acyclovir for up to 6 years, valacyclovir and famciclovir for at least 1 year 1
- Reassessment strategy: After 1 year of continuous suppressive therapy, discontinue medication to reassess recurrence frequency, as recurrences naturally decrease over time in many patients 1, 2
- No laboratory monitoring required unless substantial renal impairment exists 4
Critical Counseling Points
Transmission Risk Reduction:
- Suppressive therapy reduces but does not eliminate asymptomatic viral shedding and transmission risk 1, 2
- Condom use should be encouraged during all sexual exposures, even on suppressive therapy 1, 2
- Abstain from sexual activity when lesions or prodromal symptoms are present 1, 2
Natural History Education:
- Asymptomatic viral shedding occurs more frequently with HSV-2 than HSV-1 and in the first 12 months after infection 1
- Most HSV transmission occurs during asymptomatic periods 1, 2
- Recurrence frequency typically decreases over time 1
Alternative: Episodic Therapy
For patients who prefer not to take daily medication or have infrequent recurrences, episodic therapy can be offered:
- Acyclovir 800 mg twice daily for 5 days 1
- Famciclovir 125 mg twice daily for 5 days 1
- Valacyclovir 500 mg twice daily for 5 days 1
Timing is critical: Treatment must be initiated during prodrome or within 1 day of lesion onset for benefit 1. Provide patients with a prescription to keep on hand for immediate self-initiation 1.
Special Populations
Pregnancy:
- Acyclovir is the first choice during pregnancy (most safety data) 4
- Suppressive therapy starting at 36 weeks gestation is recommended for patients with known genital herpes history 5
- Cesarean delivery indicated for active lesions at labor onset 4
Immunocompromised Patients:
- May require higher doses or more aggressive therapy 4, 2
- Monitor for acyclovir-resistant HSV if lesions fail to resolve within 7-10 days 4
- IV foscarnet is treatment of choice for acyclovir-resistant HSV 4
Common Pitfalls to Avoid
- Do not use short-course therapy (1-3 days) in HIV-infected patients 4
- Do not assume immune reconstitution eliminates need for suppression in HIV patients on ART—genital HSV shedding frequency remains unchanged despite clinical improvement 4
- Avoid topical acyclovir—substantially less effective than oral therapy 2
- Do not routinely screen asymptomatic individuals for HSV-2 6
- Resistance is rare in immunocompetent patients on suppressive therapy and has not been associated with treatment failure 1, 2